Cardiology

The REDUCE-IT trial: Icosapent ethyl reduces ischemic event risk in patients with hypertriglyceridemia despite statin use

1. After a median follow-up of 4.9 years, patients with elevated triglyceride levels despite statin use treated with icosapent ethyl had a lower risk of cardiovascular adverse events compared to patients in a placebo group. 2. Hospitalization for atrial fibrillation or flutter occurred in more patients treated with icosapent ethyl Czytaj więcej…